X0508 4 2023-03-20 0 0001534133 CalciMedica, Inc. CALC 0001306717 Sanderling Venture Partners VI LP 1300 S. EL CAMINO REAL SUITE 203 SAN MATEO CA 94402 0 0 1 0 0001306695 Sanderling Venture Partners VI Co Investment Fund LP 1300 S EL CAMINO REAL SUITE 203 SAN MATEO CA 94402 0 0 1 0 0001429588 Sanderling Ventures Management VI 1300 S EL CAMINO REAL SUITE 203 SAN MATEO CA 94402 0 0 1 0 0001429283 Sanderling VI Beteiligungs GmbH & Co KG 1300 S EL CAMINO REAL SUITE 203 SAN MATEO CA 94402 0 0 1 0 0001429282 Sanderling VI Limited Partnership 1300 S EL CAMINO REAL SUITE 203 SAN MATEO CA 94402 0 0 1 0 0001565862 Sanderling Ventures VII, L.P. 1300 S. EL CAMINO REAL SUITE 203 SAN MATEO CA 94402 0 0 1 0 0001678656 Sanderling Ventures VII Annex Fund, L.P. 1300 S EL CAMINO REAL SUITE 203 SAN MATEO CA 94402 0 0 1 0 0001993457 Sanderling Ventures Management VII 1300 S. EL CAMINO REAL SUITE 203 SAN MATEO CA 94402 0 0 1 0 0001993660 Sanderling Ventures VII (Canada), L.P. 1300 S. EL CAMINO REAL SUITE 203 SAN MATEO CA 94402 0 0 1 0 0 Common Stock 2023-03-20 4 A 0 703388 A 703388 D Common Stock 2023-03-20 4 A 0 582757 A 582757 I By Sanderling Venture Partners VI Co-Investment Fund, L.P. Common Stock 2023-03-20 4 A 0 17682 A 17682 I By Sanderling Ventures Management VI Common Stock 2023-03-20 4 A 0 7456 A 7456 I By Sanderling VI Beteligungs GmbH & Co KG Common Stock 2023-03-20 4 A 0 8884 A 8884 I By Sanderling VI Limited Partnership Common Stock 2023-03-20 4 A 0 240676 A 240676 I By Sanderling Ventures VII, L.P. Common Stock 2023-03-20 4 A 0 14425 A 14425 I By Sanderling Ventures VII Annex Fund, L.P. Common Stock 2023-03-20 4 A 0 63228 A 63228 I By Sanderling Ventures VII (Canada), L.P. Common Stock 2023-03-20 4 A 0 1548 A 1548 I By Sanderling Ventures Management VII Warrant 26.74 2023-03-20 4 A 0 2672 A 2027-02-28 Common Stock 2672 2672 D Warrant 27.94 2023-03-20 4 A 0 16539 A 2026-02-22 Common Stock 16539 16539 D Warrant 27.94 2023-03-20 4 A 0 2685 A 2026-06-25 Common Stock 2685 2685 D Warrant 26.74 2023-03-20 4 A 0 1910 A 2027-02-28 Common Stock 1910 1910 I By Sanderling Venture Partners VI Co-Investment Fund, L.P. Warrant 27.94 2023-03-20 4 A 0 6852 A 2026-02-22 Common Stock 6852 6852 I By Sanderling Venture Partners VI Co-Investment Fund, L.P. Warrant 27.94 2023-03-20 4 A 0 15403 A 2026-06-25 Common Stock 15403 15403 I By Sanderling Venture Partners VI Co-Investment Fund, L.P. Warrant 27.94 2023-03-20 4 A 0 237 A 2026-03-04 Common Stock 237 237 I By Sanderling Ventures Management VI Warrant 27.94 2023-03-20 4 A 0 183 A 2026-06-25 Common Stock 183 183 I By Sanderling Ventures Management VI Warrant 27.94 2023-03-20 4 A 0 8393 A 2026-02-22 Common Stock 8393 8393 I By Sanderling Ventures VII, LP Warrant 27.94 2023-03-20 4 A 0 12380 A 2026-06-25 Common Stock 12380 12380 I By Sanderling Ventures VII, LP Warrant 27.94 2023-03-20 4 A 0 2203 A 2026-03-04 Common Stock 2203 2203 I By Sanderling Ventures VII (Canada), LP Warrant 27.94 2023-03-20 4 A 0 3249 A 2026-06-25 Common Stock 3249 3249 I By Sanderling Ventures VII (Canada), LP Warrant 27.94 2023-03-20 4 A 0 569 A 2026-03-04 Common Stock 569 569 I By Sanderling Ventures VII Annex Fund, L.P. Warrant 27.94 2023-03-20 4 A 0 840 A 2026-06-25 Common Stock 840 840 I By Sanderling Ventures VII Annex Fund, L.P. Warrant 27.94 2023-03-20 4 A 0 113 A 2026-03-04 Common Stock 113 113 I By Sanderling Ventures Management VII Warrant 27.94 2023-03-20 4 A 0 167 A 2026-06-25 Common Stock 167 167 I By Sanderling Ventures Management VII Received in exchange for 24,423,158 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. Received in exchange for 20,234,606 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for 613,943 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for 258,883 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for 308,455 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for 8,356,779 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for 500,854 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for 2,195,354 shares of the common stock of CalciMedica pursuant to the Merger Agreement. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Received in exchange for 53,733 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Immediately exercisable. Received in exchange for a warrant to purchase 92,748 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 574,269 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 93,225 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 66,305 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 237,911 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 534,815 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 8,203 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 6,343 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 291,407 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 429,837 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 76,470 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 112,796 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 19,754 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 29,139 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 3,915 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a warrant to purchase 5,775 shares of common stock of CalciMedica pursuant to the Merger Agreement. Sanderling Venture Partners VI , L.P., By: /s/ Fred Middleton, Managing Director of Middleton, McNeil & Mills Associates VI, L.P., its General Partner 2023-10-10 Sanderling Venture Partners VI Co-Investment Fund, L.P., By: /s/ Fred Middleton, Managing Director of Middleton, McNeil & Mills Associates VI, LLC, its General Partner 2023-10-10 Sanderling Ventures Management VI, By: /s/ Fred Middleton, Owner 2023-10-10 Sanderling VI Beteiligungs GmbH & Co. KG, By: /s/ Fred Middleton, Managing Director of Middleton, McNeil & Mills Associates VI, LLC, its Managing Limited Partner 2023-10-10 Sanderling VI Limited Partnership, By: /s/ Fred Middleton, Managing Director of Middleton, McNeil & Mills Associates VI, LLC, its Investment General Partner 2023-10-10 Sanderling Ventures VII, L.P. , By: /s/ Fred Middleton, Managing Director of M4 Partners VII, LLC, its General Partner 2023-10-10 Sanderling Ventures VII Annex Fund, L.P., By: /s/ Fred Middleton, Managing Director of M4 Partners VII Annex, LLC, its General Partner 2023-10-10 Sanderling Ventures Management VII, By: /s/ Fred Middleton, Owner 2023-10-10 Sanderling Ventures VII (Canada), L.P., By: /s/ D. Michael Dixon, President of Sanderling Ventures VII (Canada) GP Inc., General Partner of Sanderling Ventures VII (Canada) G.P., L.P, its General Partner 2023-10-10